Research
Pygeum africanum (African Cherry Bark)
8 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Pygeum africanum for benign prostatic hyperplasia.
Systematic review of 18 randomized controlled trials involving 1562 men with benign prostatic hyperplasia (BPH) assessing the effectiveness of Pygeum africanum. The review found that Pygeum africanum provided a moderately large improvement in urologic symptoms and flow measures compared to placebo, with mild adverse effects comparable to placebo. However, the studies were small, short in duration, and varied in doses and preparations.
Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.
Systematic review and meta-analysis of 18 RCTs involving 1,562 men with benign prostatic hyperplasia. Pygeum africanum showed a moderately large improvement in urologic symptoms and flow measures compared to placebo. Adverse effects were mild and similar to placebo. The evidence suggests modest but significant improvements, though further research is needed for long-term effectiveness.
Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension.
RCT comparing the efficacy and safety of Pygeum africanum extract in two dosage forms (50 mg twice daily and 100 mg once daily) in patients with benign prostatic hyperplasia. Both treatments showed similar efficacy, with improvements in IPSS, QOL, and Qmax. Long-term open phase showed further improvements with a satisfactory safety profile.
[Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study].
A multicentre double-blind RCT tested the efficacy of Pygeum africanum extract in treating urination disorders due to benign prostatic hyperplasia. 263 patients received either 50 mg of Pygeum africanum extract or placebo for 60 days. The Pygeum africanum group showed significant improvement in both objective and subjective parameters compared to placebo, with 66% of patients reporting improvement in micturition.
Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe.
This multicentre trial evaluated the efficacy and safety of Pygeum africanum extract (Tadenan) in treating benign prostatic hyperplasia (BPH) in men aged 50-75. Over a two-month treatment period, significant improvements were observed in International Prostate Symptom Score (IPSS), quality of life, and urinary flow parameters. These effects persisted one month after stopping treatment, with no adverse effects reported.
Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses.
RCT of 134 patients with benign prostatic hyperplasia comparing two doses of Urtica dioica and Pygeum africanum extract. Both doses significantly reduced urine flow, residual urine, and nycturia after 28 and 56 days. No significant differences between doses in efficacy, and both were well-tolerated.
[Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma].
RCT with two groups of 60 patients each, one receiving pygeum africanum extract and the other a placebo. The extract provided an overall improvement in functional symptoms of prostatic adenoma, with statistically significant differences in nocturnal frequency, difficulty in starting micturition, and incomplete emptying of the bladder.
Anti-Inflammatory Potential of Pygeum africanum Bark Extract: An In Vitro Study of Cytokine Release by Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells
In vitro study assessing the anti-inflammatory potential of Pygeum africanum bark extract on cytokine release from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. The extract significantly decreased IL-6, IL-2, IL-4, IL-5, IL-9, IL-13, IL-27, and TNF-α levels, supporting its potential use in managing BPH and other inflammatory conditions.